Cannabis Law Report

FEBRUARY 16, 2022

In the fourth event of our Psychedelic Revival series, we’ll discuss the current research being conducted, clinical applications and ways to get involved through training, community programs, intercollegiate clubs, harm reduction, research, and beyond. A Journey Through the Psychedelic Revival: Access to Psychedelic Medicine.

Events 52

Events Medicine Therapy Decriminalization 52

Cannabis Law Report

MAY 28, 2021

CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“ Field Trip “), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has received conditional approval to list its common shares and warrants on the Toronto Stock Exchange (TSX). TORONTO, May 27, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd.

Conditions 98

Conditions Research and Development Therapy Events 98

NORML

MARCH 1, 2019

Senate Bill 19-013 would permit physicians to recommend cannabis therapy for any condition for which an opiate would otherwise be prescribed. House Bill 19-1028 would permit physicians to recommend cannabis therapy to those diagnosed with an autism spectrum disorder. GA resident? MD resident? MN resident? NM resident?

Legislation 185

Legislation Compliance Compliance Hemp 185

SpeedWeed

MARCH 26, 2021

That’s just one step being taken to prepare the state for the eventual implementation of Measure 109, in which 56 percent of voters approved last fall to legalize psychedelic mushroom therapy. . The post This New BIPOC-Run Group Is Educating People About Legal Mushroom Therapy in Oregon appeared first on SpeedWeed.

Therapy 52

Therapy Education Legalization Media 52

Veriheal

AUGUST 21, 2023

The $5 million donation will assist the fund, providing financial assistance to individuals needing access to MDMA therapy. Other drugs like MDMA subsequently emerged and were explored during psychedelic-inclined therapies. Substances like psilocybin, MDMA, and LSD have been the subject of these therapies.

Therapy 95

Therapy Research and Development Treatment Environment 95

Cannabis Law Report

JANUARY 26, 2022

MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021. MAPS Public Benefit Corporation will coordinate trial design with Medicines and Healthcare products Regulatory Agency to create a road map for early patient access in the UK. Corine de Boer, M.D.,

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in psilocybin therapy, and it was done amid the lockdowns and challenges of the COVID pandemic. million, or $0.79 million, or $2.61

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JUNE 14, 2022

Those values guide our joint efforts to change perceptions about psychedelic assisted therapies, raise awareness of the scientific advances and, ultimately, bring better health to European citizens. Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD.

Access 52

Access Therapy Clinical Trials Treatment 52

Veriheal

JUNE 29, 2022

The study was conducted by COMPASS Pathways , a mental healthcare company that is “dedicated to accelerating patient access to evidence-based innovation in mental health.” Adverse Events : This finding category refers to suicidal ideation and intentional self-injury, which were seen in all of the treatment groups.

Clinical Trials 105

Clinical Trials Blood Pressure Treatment Therapy 105

Veriheal

JUNE 30, 2023

To start, participants reported that psilocybin had helped them process emotions tied to painful events in their past. Researchers say this emphasizes just how important it is that psilocybin therapy be done in a controlled setting with therapy and community-based after-care.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

TheAnswerPage

JANUARY 11, 2022

the components of the cannabis plant (phytocannabinoids, terpenes, and flavonoids) and the health effects of cannabinoid-based therapy in the various patient populations. Who monitors their health and the long-term effects of the marijuana therapy?

Patients 98

Patients Education Marijuana Therapy 98

MMJ Recs

JULY 11, 2024

It is often caused by life events such as stress, anxiety, or a significant change in routine. Each type of insomnia may require different treatment approaches, including behavioral therapy, medication, lifestyle changes, or addressing underlying medical or psychological issues.

Sleep 111

Sleep Treatment Research and Development Therapy 111

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. a global leader in the cannabis industry serving both medical and consumer markets and dedicated to helping people improve their lives. .

Programs 100

Programs Data Events Collective 100

Project CBD

DECEMBER 31, 2022

Setting aside for a minute how effective psychedelics may or may not be as breakthrough treatments for PTSD , there’s no doubt that cannabis is still much easier for most patients to access. Adverse events related to cannabis use were predominately mild or moderate, with insomnia and fatigue being most common at 20 incidents each.

Sleep 130

Sleep Patients Treatment Cannabis 130

Cannabis Law Report

JUNE 19, 2022

A new alliance aiming to help hone the therapeutic potential of psychedelics is set to emerge from Europe, making its debut via a virtual event later this month. We are equally excited about the inaugural launch of the Psychedelic Access and Research European Alliance! Closing remarks and the launch of a Call to Action ??will

Therapy 52

Therapy Advocacy Events Treatment 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.” ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.

Research and Development 52

Research and Development Therapy Clinical Trials Safety 52

Cannabis Law Report

JULY 28, 2021

This direct access to patients and clinics is expected to differentiate KGK from other CROs by providing the opportunity to study patients with differing demographics across various populations, while also shortening recruitment timelines for studies. The recent addition of KGK Science Inc. On behalf of: KETAMINE ONE.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

JANUARY 20, 2022

Event Details. Emmer is the vice president of the healthcare practice at Field Trip Health , a mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. Mon, Jan 24, 2022 at 6:30 PM. Ludlow House, 139 Ludlow St, New York, NY, 10002. More info: [link].

Therapy 52

Therapy Research and Development Access Events 52

Cannabis Law Report

JUNE 29, 2022

The worlds of cannabis and psychedelics are coming together in a single event to dispel stigmas, promote science, and battle the mental health crisis. The event is the most accessible of its kind offering free admission for all to its expo and networking floor. Event details are as follows. About Cannadelic.

Events 52

Events Education Therapy Access 52

Cannabis Law Report

JUNE 17, 2021

Silo Wellness is a publicly traded company on the CSE with a consumer-facing platform for the sale of functional mushroom products, psilocybin mushroom production in Jamaica, and the facilitation of psychedelic wellness retreats in both Jamaica and Oregon that incorporate a variety of psychedelic-augmented therapies.

Research and Development 75

Research and Development Therapy Access Media 75

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression. While psychedelic therapies make their way through the drug development pipeline, seven U.S. The Role of Psychedelics in Healing Trauma.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

AUGUST 3, 2021

ADCL’s solution includes the use of subcontractor CLEARED4’s health verification platform for appointments, sample tracking, and value-add services of campus access management. As prime contractor, ADCL will also provide on-site staffing and sample transport and logistics. For Applied DNA: Investor contact: Sanjay M.

Clinical Trials 81

Clinical Trials Therapy Collective Research and Development 81

Cannabis Law Report

SEPTEMBER 2, 2021

ADCL will serve as prime contractor with subcontractor CLEARED4’s health verification platform to be used for appointments, sample tracking, reporting, program management, and mobile access pass visibility. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology.

Clinical Trials 76

Clinical Trials Research and Development Therapy Collective 76

Cannabis Law Report

DECEMBER 1, 2021

As psychedelic medicine becomes more mainstream, we must ensure that all who participate in healing therapeutic sessions, both above ground and in ceremonial or underground therapeutic settings, are safe and accessible to all. Emma teaches classes on integrating kink-based consent practices into psychedelic-assisted therapy.

Safety 52

Safety Medicine Therapy Research and Development 52

SpeedWeed

JULY 6, 2021

By analyzing social, legal, and political barriers to access in this context, we hope to advance the understanding of their potential impact as therapeutics.”. The project also intends to advance research into how psychedelics can heal trauma and how to ensure equitable access to these therapies.

Policy 52

Policy Law Research and Development Therapy 52

Veriheal

FEBRUARY 28, 2021

It helps to showcase the 103 countries holding events on this day as well as the thousands of events hosted online worldwide. This year, COVID-19 has dramatically impacted the way events are hosted. Instead of having physical locations, many events have opted to go digital being held online.

Chronic Pain 52

Chronic Pain Events Therapy Treatment 52

Cannabis Law Report

JULY 7, 2021

As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy. The recent addition of KGK Science Inc. On behalf of: KETAMINE ONE. ” Adam Deffett ” Adam Deffett, Interim CEO. For further information, please contact: Nick Kuzyk, Investor Relations.

Research and Development 98

Research and Development Treatment Therapy Banking 98

Cannabis Life Network

NOVEMBER 18, 2020

The compassionate access clinical trial will enable the company to refine optimal protocols for the use of psilocybin-assisted psychotherapy for participants with a range of substance use disorders. Vancouver based Numinus Wellness Inc. announced early this morning that it will undertake a clinical trial of psilocybin-assisted psychotherapy.

Clinical Trials 98

Clinical Trials Access Therapy Events 98

Veriheal

MAY 23, 2023

Heightened expectations have trailed this approval, as many—particularly investors—heartily look forward to the big day when people can access this potentially therapeutic drug. Disappointingly, there are still no licensed recreational service centers for customers to access controlled psilocybin.

Access 89

Access Environment Topical Extraction 89

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. In MAPS’ 36th year, we’ll learn if our second Phase 3 study of MDMA-assisted therapy for PTSD was successful. The FDA received MAPS’ protocol for a new study of MDMA-assisted therapy for PTSD.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Shared mission of responsibly reintroducing psychedelic therapy to mental healthcare. “Since Numinus began, we have always strived to be the most trusted, evidence-based leader in psychedelic-assisted therapy and medicine. NEWS PROVIDED BY. ” Mr. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Puff Puff Post

NOVEMBER 30, 2018

In fact, the Canadian Veterinary Medical Association has teamed up with a group supporting cannabinoid therapy for animals, the Canadian Association of Veterinary Cannabinoid Medicine. They want to push for access to CBD oil to treat sick animals. On NSAID therapy, however, the dogs’ creatinine levels increased.

Pets 76

Pets Oil CBD Research and Development 76

Cannabis Law Report

MAY 18, 2022

With few solutions in sight, there is a growing body of evidence that suggests that psychedelic-assisted therapy could provide a breakthrough in treating countless mental health ailments, such as depression, substance abuse disorders, and PTSD. The clinical evidence for psychedelic assisted therapy is accumulating.

Research and Development 52

Research and Development Therapy Treatment Policy 52

SpeedWeed

MARCH 13, 2021

As a result, many PD patients now have legal access to cannabis as an alternative or complementary therapy. To learn more about the effectiveness of cannabis as a treatment for PD, a survey was sent to more than 7,600 people who had interacted with the Parkinson’s Foundation through events or the group’s helpline.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

JANUARY 5, 2022

W hile this Review focuses on 2021, it’s difficult to contextualise the levels of psychedelic drug policy reform witnessed this year without appreciating the gravitas of events in late 2020. 2020 was a groundbreaking year for psychedelics decriminalisation and legalisation efforts, with the U.S.

Policy 52

Policy Therapy Banking Events 52

Cannabis Law Report

SEPTEMBER 14, 2021

This online event is the first of its kind to offer a platform for voices that are routinely left out of the so-called “Psychedelic Renaissance,” providing decolonial perspectives on the ritual, therapeutic, scientific, cultural, and philosophical aspects of psilocybin and sacred mushrooms. Via Synapsis/ Chacruna Institute.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Cannabis Law Report

NOVEMBER 9, 2021

Delic has been focused on opening locations in secondary cities with considerable demand, in an effort to provide access to the most patients. They are an industry leader and uphold the highest standards in developing new, science-backed medicines and treatments and making them more accessible to a wider group of people.

Treatment 52

Treatment Therapy Media Access 52